title: International Organization of Physical Therapy in Mental Health consensus on physical activity within multidisciplinary rehabilitation programmes for minimising cardio-metabolic risk in patients with schizophrenia.
abstract: OBJECTIVE
  The excess cardiovascular morbidity associated with schizophrenia is attributed to an interplay between behavioural (physical inactivity, unhealthy diet, substance abuse), genetic and illness related factors, as well as the effects of antipsychotic treatment. Patients have limited access to physical healthcare with less opportunity for cardiovascular risk prevention and treatment programmes than the non-psychiatric population. The aim of this paper is to improve physical activity (PA) within rehabilitation programmes for people with schizophrenia.
  
  
  METHODS
  The development process consisted of: a) systematic literature review on PA in schizophrenia in eight databases up to May 2010; b) review on existing national and international guidelines; c) consensus meetings, and d) formulation of the final consensus document.
  
  
  RESULTS
  There is insufficient evidence for the relative contribution of PA reducing cardio-metabolic risks in people with schizophrenia. Demographical, biological, psychological, cognitive-behavioural, emotional, social and environmental barriers for PA could be identified.
  
  
  CONCLUSIONS
  Although PA outcomes on cardio-metabolic parameters are still unknown, the benefits of physical activity as part of a larger lifestyle programme are sufficient for the recommendation that persons with schizophrenia follow the 2008 U.S. Department of Health and Human Services PA Guidelines with specific adaptations based on disease and treatment-related adverse effects.
authors.affiliation: University Psychiatric Centre Catholic University Leuven, Kortenberg, Belgium. Davy.Vancampfort@uc-kortenberg.be
authors.forename: Davy
authors.initials: D
authors.lastname: Vancampfort
authors.forename: Marc
authors.initials: M
authors.lastname: De Hert
authors.forename: Liv Helvik
authors.initials: LH
authors.lastname: Skjerven
authors.forename: Amanda Lundvik
authors.initials: AL
authors.lastname: Gyllensten
authors.forename: Anne
authors.initials: A
authors.lastname: Parker
authors.forename: Nathalie
authors.initials: N
authors.lastname: Mulders
authors.forename: Lene
authors.initials: L
authors.lastname: Nyboe
authors.forename: Felicity
authors.initials: F
authors.lastname: Spencer
authors.forename: Michel
authors.initials: M
authors.lastname: Probst
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control*; D004185:Disability Evaluation; D006293:Health Promotion / Q000379:methods*; D006297:Health Services Accessibility; D006801:Humans; D008019:Life Style; D009043:Motor Activity; D009938:Organizations; D012307:Risk Factors; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents